Clinical Trials Browser

Has results × Primary Myelofibrosis × ruxolitinib × Clear all

Neoplasms, Primary Myelofibrosis

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT04551066 2025-10-21

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Phase 3 Terminated

252 enrolled 18 charts

Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04551053 2025-10-02

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Phase 3 Terminated

177 enrolled 15 charts

Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT01375140 2025-06-08

Ruxolitinib and Lenalidomide for Patients With Myelofibrosis

Phase 2 Completed

31 enrolled 8 charts

Myeloid

Polycythemia Vera, Primary Myelofibrosis

NCT04281498 2025-02-04

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Phase 2 Completed

6 enrolled 11 charts

Myeloid

Primary Myelofibrosis

NCT02718300 2024-05-01

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Phase 2 Terminated

74 enrolled 40 charts

Myeloid

Myeloproliferative Disorders, Hereditary Sensory and Autonomic Neuropathies, Primary Myelofibrosis

NCT01712308 2023-10-10

Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia

Phase 2 Completed

56 enrolled 9 charts

Classical hematologyMyeloid

Anemia, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT03144687 2022-06-16

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

Phase 2 Completed

23 enrolled 31 charts

Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT01981850 2022-01-05

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

Phase 2 Completed

125 enrolled 38 charts

Myeloid

Fibrosis, Polycythemia Vera, Primary Myelofibrosis

NCT02587598 2021-12-08

Study of INCB053914 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

97 enrolled 40 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT01369498 2020-07-01

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Phase 2 Completed

54 enrolled 16 charts

MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Primary Myelofibrosis

NCT01787552 2020-04-15

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Phase 1/2 Completed

50 enrolled 23 charts

Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Primary Myelofibrosis

NCT02267278 2019-06-12

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)

Phase 2 Completed

25 enrolled 8 charts

Myeloid

Polycythemia Vera, Primary Myelofibrosis

NCT00509899 2018-03-12

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Phase 1/2 Completed

154 enrolled 26 charts

Myeloid

Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

NCT00952289 2018-03-12

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

Phase 3 Completed

309 enrolled 18 charts

Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT01340651 2014-03-10

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

Phase 2 Completed

41 enrolled 15 charts

Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

Clinical Trials

TRANSFORM-1

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Ruxolitinib and Lenalidomide for Patients With Myelofibrosis

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

Study of INCB053914 in Subjects With Advanced Malignancies

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients